mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®Miguel Martínez-Cava2025-12-22T22:02:19+01:00December 22, 2025|Press releases|
mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar developmentMiguel Martínez-Cava2025-12-17T10:19:49+01:00December 4, 2025|Press releases|
mAbxience announces European Commission approval of denosumab biosimilarsadriana.polo2025-07-02T15:00:56+02:00July 2, 2025|Press releases|
What does a company have in common with a cell?adriana.polo2025-11-12T12:02:38+01:00November 12, 2025|News|
Can AI optimizations impact every stage of a biologic production process?Bruno Martín2025-09-03T15:57:35+02:00September 3, 2025|News|
The science behind trust: how biosimilars are developed, proven and delivered to patientsBruno Martín2025-07-28T13:03:51+02:00July 28, 2025|News|
